Thyroid cytology: Difference between revisions

Line 46:

File:Cytology of benign follicular epithelial cells.jpg|Cytology of benign follicular epithelial cells (Bethesda category II), Pap stain, showing cells with significant nuclear pleomorphism but otherwise insignificant features.

File:Pie chart of relative incidences of thyroid cancers.png|Relative incidences of '''malignant''' thyroid tumors.

File:Cytology ~~'''~~suspicious for Hürthle cell neoplasm~~'''~~, annotated.png|Cytopathology suspicious for Hürthle cell neoplasm (Bethesda category IV), Pap stain. However, it cannot distinguish Hürthle cell adenoma from Hürthle cell carcinoma, which requires histopathologic sections to see transcapsular or vascular invasion. Hürthle cell hyperplasia (as seen in Hashimoto's thyroiditis) may show moderate variation in nuclear sizes and prominent nucleoli, but further findings favoring Hürthle cell neoplasm include a large number of Hürthle cells, and discohesiveness.<ref>Image by Mikael Häggström, MD. References for findings:<br>- {{cite web|url=https://www.pathologyoutlines.com/topic/thyroidhurthlecellneoplasm.html|title=Hürthle cell neoplasm|website=Pathology Outlines|author=Ayana Suzuki, C.T., Andrey Bychkov, M.D., Ph.D.}} Last author update: 7 May 2020. Last staff update: 12 May 2022<br>- {{cite journal| author=Shawky M, Sakr M| title=Hurthle Cell Lesion: Controversies, Challenges, and Debates. | journal=Indian J Surg | year= 2016 | volume= 78 | issue= 1 | pages= 41-8 | pmid=27186039 | doi=10.1007/s12262-015-1381-x | pmc=4848220 | url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4848220/}}</ref>

File:Cytology suspicious for Hürthle cell neoplasm, annotated.png|Cytopathology '''suspicious for Hürthle cell neoplasm''' (Bethesda category IV), Pap stain. However, it cannot distinguish Hürthle cell adenoma from Hürthle cell carcinoma, which requires histopathologic sections to see transcapsular or vascular invasion. Hürthle cell hyperplasia (as seen in Hashimoto's thyroiditis) may show moderate variation in nuclear sizes and prominent nucleoli, but further findings favoring Hürthle cell neoplasm include a large number of Hürthle cells, and discohesiveness.<ref>Image by Mikael Häggström, MD. References for findings:<br>- {{cite web|url=https://www.pathologyoutlines.com/topic/thyroidhurthlecellneoplasm.html|title=Hürthle cell neoplasm|website=Pathology Outlines|author=Ayana Suzuki, C.T., Andrey Bychkov, M.D., Ph.D.}} Last author update: 7 May 2020. Last staff update: 12 May 2022<br>- {{cite journal| author=Shawky M, Sakr M| title=Hurthle Cell Lesion: Controversies, Challenges, and Debates. | journal=Indian J Surg | year= 2016 | volume= 78 | issue= 1 | pages= 41-8 | pmid=27186039 | doi=10.1007/s12262-015-1381-x | pmc=4848220 | url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4848220/}}</ref>

</gallery>

@@ Line 46: / Line 46: @@
 File:Cytology of benign follicular epithelial cells.jpg|Cytology of benign follicular epithelial cells (Bethesda category II), Pap stain, showing cells with significant nuclear pleomorphism but otherwise insignificant features.
 File:Pie chart of relative incidences of thyroid cancers.png|Relative incidences of '''malignant''' thyroid tumors.
-File:Cytology '''suspicious for Hürthle cell neoplasm''', annotated.png|Cytopathology suspicious for Hürthle cell neoplasm (Bethesda category IV), Pap stain. However, it cannot distinguish Hürthle cell adenoma from Hürthle cell carcinoma, which requires histopathologic sections to see transcapsular or vascular invasion. Hürthle cell hyperplasia (as seen in Hashimoto's thyroiditis) may show moderate variation in nuclear sizes and prominent nucleoli, but further findings favoring Hürthle cell neoplasm include a large number of Hürthle cells, and discohesiveness.<ref>Image by Mikael Häggström, MD. References for findings:<br>- {{cite web|url=https://www.pathologyoutlines.com/topic/thyroidhurthlecellneoplasm.html|title=Hürthle cell neoplasm|website=Pathology Outlines|author=Ayana Suzuki, C.T., Andrey Bychkov, M.D., Ph.D.}} Last author update: 7 May 2020. Last staff update: 12 May 2022<br>- {{cite journal| author=Shawky M, Sakr M| title=Hurthle Cell Lesion: Controversies, Challenges, and Debates. | journal=Indian J Surg | year= 2016 | volume= 78 | issue= 1 | pages= 41-8 | pmid=27186039 | doi=10.1007/s12262-015-1381-x | pmc=4848220 | url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4848220/}}</ref>
+File:Cytology suspicious for Hürthle cell neoplasm, annotated.png|Cytopathology '''suspicious for Hürthle cell neoplasm''' (Bethesda category IV), Pap stain. However, it cannot distinguish Hürthle cell adenoma from Hürthle cell carcinoma, which requires histopathologic sections to see transcapsular or vascular invasion. Hürthle cell hyperplasia (as seen in Hashimoto's thyroiditis) may show moderate variation in nuclear sizes and prominent nucleoli, but further findings favoring Hürthle cell neoplasm include a large number of Hürthle cells, and discohesiveness.<ref>Image by Mikael Häggström, MD. References for findings:<br>- {{cite web|url=https://www.pathologyoutlines.com/topic/thyroidhurthlecellneoplasm.html|title=Hürthle cell neoplasm|website=Pathology Outlines|author=Ayana Suzuki, C.T., Andrey Bychkov, M.D., Ph.D.}} Last author update: 7 May 2020. Last staff update: 12 May 2022<br>- {{cite journal| author=Shawky M, Sakr M| title=Hurthle Cell Lesion: Controversies, Challenges, and Debates. | journal=Indian J Surg | year= 2016 | volume= 78 | issue= 1 | pages= 41-8 | pmid=27186039 | doi=10.1007/s12262-015-1381-x | pmc=4848220 | url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4848220/}}</ref>
 </gallery>
 {{Bottom}}

Thyroid cytology: Difference between revisions

Navigation menu

Search